Is Aurobindo Pharma Ltd debt-free?

Yes, Aurobindo Pharma Ltd is debt-free with a debt-to-equity ratio of 0.23.

Home

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd Financials

Aurobindo Pharma Ltd Financial Statement

Aurobindo Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Jun 2025	Mar 2025	Dec 2024
Revenue	2,931.94	2,845.97	2,970.89
Operating Expense	2,051.83	2,135.48	2,203.48
Net Profit	559.13	408.17	472.05
Net Profit Margin	19.07	14.34	15.89
Earning Per Share	9.63	7.03	8.13
EBIDTA	876.83	718.39	770.55
Effective Tax Rate	21.32	21.85	21.37

Particulars	Jun 2025
Revenue	2931.94
Operating Expense	2051.83
Net Profit	559.13
Net Profit Margin	19.07
Earning Per Share	9.63
EBIDTA	876.83
Effective Tax Rate	21.32

Aurobindo Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	10,645.64	8,457	11,287.14
Operating Expenses Annual	8,421.60	6,952.09	9,813.74
Operating Profit Annual	2,894.14	1,933.77	2,069.68
Interest Annual	182.60	74.58	16.94
Depreciation	236.72	219.12	411.53
Net Profit Annual	1,900.10	1,242.17	1,454.71
Tax Annual	502.82	388.82	182.77

Particulars	Mar 2024
Total Revenue Annual	10,645.64
Operating Expenses Annual	8,421.60
Operating Profit Annual	2,894.14
Interest Annual	182.60
Depreciation	236.72
Net Profit Annual	1,900.10
Tax Annual	502.82

Aurobindo Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	357.13	51.13	383.58
Cash Flow from Operations	1,714.80	1,816.17	3,726.71
Cash Flow from Investing	-151.58	-3,229.65	-1,614.54
Cash Flow from Financing	-1,837.03	1,719.48	-2,447.54
Cash Flow at the End	83.32	357.13	48.21

Particulars	Mar 2024
Cash Flow at the Beginning	357.13
Cash Flow from Operations	1,714.80
Cash Flow from Investing	-151.58
Cash Flow from Financing	-1,837.03
Cash Flow at the End	83.32

Aurobindo Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	27.19	22.87	18.34
PBIT Margin (%)	24.79	19.99	14.66
PBT Margin (%)	24.65	19.72	13.79
Net PROFIT Margin (%)	18.36	14.51	12.89
Return On Networth / Equity (%)	10.35	6.98	8.81
Return On Networth /Employed (%)	11.74	8.18	8.49
Return On Assets (%)	8.63	5.95	7.48
Total Debt / Equity (X)	0.19	0.17	0.18
Asset Turnover Ratio (%)	0.47	0.41	0.58

Particulars	Mar 2024
PBDIT Margin (%)	27.19
PBIT Margin (%)	24.79
PBT Margin (%)	24.65
Net PROFIT Margin (%)	18.36
Return On Networth / Equity (%)	10.35
Return On Networth /Employed (%)	11.74
Return On Assets (%)	8.63
Total Debt / Equity (X)	0.19
Asset Turnover Ratio (%)	0.47

Aurobindo Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	2,419.13	3,687.50	3,585.83
Total Current Assets Annual	7,239.13	9,964.99	9,835.11
Non Current Assets Annual	17,914.85	15,093.82	11,765.84
Total Shareholders Funds Annual	19,722.82	18,034.03	17,117.34
Total Assets Annual	25,153.98	25,058.81	21,600.95

Particulars	Mar 2024
Fixed Assets Annual	2,419.13
Total Current Assets Annual	7,239.13
Non Current Assets Annual	17,914.85
Total Shareholders Funds Annual	19,722.82
Total Assets Annual	25,153.98

Aurobindo Pharma Ltd Earning Calls

EPS (INR)

Expected

14.20

Reported

14.20

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Dividend Pages

PE Ratio

FAQS on Aurobindo Pharma Ltd Financials

As of Aug 8, 2025, Aurobindo Pharma Ltd has a market capitalization of 67,951.30 Cr. Value Research classifies it as a Large-Cap company.

Yes, Aurobindo Pharma Ltd is with a debt-to-equity ratio of 0.23.

In FY 2024 , Aurobindo Pharma Ltd recorded a total revenue of approximately 10,788.09 Cr marking a significant milestone in the company's financial performance.

Aurobindo Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..

Aurobindo Pharma Ltd's current PE ratio is 38.90.

Aurobindo Pharma Ltd's ROCE averaged 9.9% from the FY ending March 2023 to 2025, with a median of 10.3%. It peaked at 11.7% in March 2024, reflecting strong capital efficiency over the period..

Aurobindo Pharma Ltd's latest EBIT is Rs. 2,588.49 Cr, surpassing the average EBIT of Rs. 2,306.19 Cr over the 5 years..